188913-58-8

Usage

InChI:InChI=1/C36H33N5O4/c1-24-37-32-9-5-6-10-33(32)41(24)23-25-17-19-40(20-18-25)35(43)22-30(26-7-3-2-4-8-26)27-11-13-28(14-12-27)38-39-29-15-16-34(42)31(21-29)36(44)45/h2-16,21-22,25,38H,17-20,23H2,1H3,(H,44,45)/b30-22-,39-29+

Upstream product

• 21320-81-0 ethyl 3-(4-nitrophenyl)-3-phenylacrylate 
• 188913-63-5 1-[4-(2-methyl-imidazo[4,5-c]pyridin-1-ylmethyl)-piperidin-1-yl]-3-(4-nitro-phenyl)-3-phenyl-propenone 
• 173604-54-1 1-[(4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine 
• 17683-99-7 E/Z-3-(4-nitrophenyl)-3-phenylpropenoic acid 
• 1144-74-7 4-nitrobenzophenone 
• 69-72-7 salicylic acid 
• 179173-99-0 cis-1-[[1-[3-(4-Aminophenyl)-3-phenylpropenoyl]-4-piperidyl]methyl]-1H-2-methylimidazo[4,5-c]pyridine 
• 179173-54-7 1-[4-(2-methyl-imidazo[4,5-c]pyridin-1-ylmethyl)-piperidin-1-yl]-3-(4-nitro-phenyl)-3-phenyl-propenone 
• 365426-14-8 ethyl (2Z)-3-(4-nitrophenyl)-3-phenylprop-2-enoate 
• 17683-99-7 (Z)-3-(4-nitrophenyl)-3-phenylpropenoic acid 
• 179173-55-8 UR 12715 

Relevant academic research and scientific papers

Method of inhibiting the production and/or effects of intestinal pro-inflammatory cytokines, prostaglandins and others

The present invention shows that UR-12746-S, a novel locally acting compound which combines 5-ASA (an anti-inflammatory) and UR-12715 (a PAF antagonist) through an azo link, and analogous azo derivatives of 5-aminosalicylic acid compounds are able to inhibit cytokine production (IL-8, IL-1β and TNF-α) in vitro, and are shown to have intestinal anti-inflammatory activity in vivo. Moreover, daily oral administration of azo derivatives of 5-aminosalicylic acid sodium salts are able to alleviate and/or prevent relapse of inflammatory disease induced in colitic rats. This beneficial effect is evidenced by a significant reduction in colonic myeloperoxidase activity and by a significant decrease in colonic IL-1β and TNF-α.

Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity

This paper describes the synthesis of a series of azo compounds able to deliver 5-aminosalicylic acid (5-ASA) and a potent platelet activating factor (PAF) antagonist in a colon-specific manner for the purpose of treating ulcerative colitis. We found it p

Azo derivatives of 5-aminosalicylic acid

Compounds of formula I and their salts and solvates are useful for the treatment or prevention of inflammatory bowel disease. Pharmaceutical compositions including these compounds and processes for their preparation are also provided. STR1